Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | HRH1 | P35367 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12694263 | 1.00 | RAB9A (0.41) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL294332 | 1.00 | RAB9A (0.41) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13104826 | 1.00 | RAB9A (0.41) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28822429 | 0.84 | KDM4E (0.40) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18595067 | 0.83 | SMN1; SMN2 (0.37) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL295095 | 0.81 | KDM4E (0.38) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL26828373 | 0.80 | CYP2D6 (0.39) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL8507646 | 0.80 | ATM (0.37) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12041542 | 0.79 | KDM4E (0.37) | RAB9AKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL30719393 | 0.79 | KDM4E (0.39) | RAB9AALDH1A1SMN1; SMN2KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2410858-B1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | RAB9A 3699/4885KMT2A 4191/4885ALDH1A1 2538/4885 |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | RAB9A 3810/4885KMT2A 4097/4885ALDH1A1 2798/4885 |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | RAB9A 986/4885KMT2A 3734/4885ALDH1A1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.